Mycobacterium bovis infection under apremilast in Behçet's syndrome

Rheumatology (Oxford). 2021 Sep 1;60(9):e301-e303. doi: 10.1093/rheumatology/keab199.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antitubercular Agents / administration & dosage
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / immunology*
  • Female
  • Humans
  • Middle Aged
  • Mycobacterium bovis / isolation & purification*
  • Phosphodiesterase 4 Inhibitors / immunology
  • Thalidomide / analogs & derivatives*
  • Thalidomide / immunology
  • Tuberculosis / drug therapy
  • Tuberculosis / immunology*
  • Tuberculosis / microbiology*

Substances

  • Antitubercular Agents
  • Phosphodiesterase 4 Inhibitors
  • Thalidomide
  • apremilast